<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: Early predictors of <z:mpath ids='MPATH_124'>infarct</z:mpath> volume may improve therapeutic decisions in patients with <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>We investigated whether measurements of serum astroglial protein S100B can predict a malignant course of infarction in <z:hpo ids='HP_0011009'>acute</z:hpo> middle cerebral artery (<z:chebi fb="70" ids="34342">MCA</z:chebi>) occlusion </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: We included 51 patients (24 women, mean age 69.1+/-12.4 years) admitted within 6 hours after <z:hpo ids='HP_0001297'>stroke</z:hpo> symptom <z:hpo ids='HP_0003674'>onset</z:hpo> caused by proximal <z:chebi fb="70" ids="34342">MCA</z:chebi> occlusion, as shown by magnetic resonance angiography (n=39), intra-arterial angiography (n=4), or transcranial duplex sonography (n=8) </plain></SENT>
<SENT sid="3" pm="."><plain>Blood samples were drawn at hospital admission and 8, 12, 16, 20, and 24 hours after symptom <z:hpo ids='HP_0003674'>onset</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Serum S100B concentrations were determined using a fully automated immunoluminometric assay </plain></SENT>
<SENT sid="5" pm="."><plain>A malignant course of infarction was defined as the occurrence of clinical signs of cerebral <z:e sem="disease" ids="C0019270" disease_type="Disease or Syndrome" abbrv="">herniation</z:e> within the first 7 days of treatment or the clinical decision to perform decompressive hemicraniectomy caused by critical space-occupying swelling as detected by repeated neuroimaging </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Sixteen patients developed malignant infarction (31%) </plain></SENT>
<SENT sid="7" pm="."><plain>Beginning with the 12-hour value, mean S100B serum concentrations were significantly higher in patients with a malignant course compared with those without (12 hours 1.23+/-1.24 versus 0.29+/-0.45 microg/L; 16 hours 1.80+/-1.65 versus 0.38+/-0.53 microg/L; 20 hours 1.90+/-1.53 versus 0.44+/-0.48 microg/L; and 24 hours 2.41+/-1.59 versus 0.57+/-0.66 microg/L; <z:hpo ids='HP_0000001'>all</z:hpo> P&lt;0.001) </plain></SENT>
<SENT sid="8" pm="."><plain>A 12-hour S100B value &gt;0.35 microg/L predicted malignant infarction with 0.75 sensitivity and 0.80 specificity </plain></SENT>
<SENT sid="9" pm="."><plain>A 24-hour value &gt;1.03 microg/L provided 0.94 sensitivity and 0.83 specificity </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: The serum marker S100B can predict a malignant course of infarction in proximal <z:chebi fb="70" ids="34342">MCA</z:chebi> occlusion </plain></SENT>
<SENT sid="11" pm="."><plain>This finding may improve the identification and monitoring of patients at particularly high risk for <z:e sem="disease" ids="C0019270" disease_type="Disease or Syndrome" abbrv="">herniation</z:e> </plain></SENT>
</text></document>